NCT03889119Active, not recruiting
Stereotactic Body Radiation Therapy (SBRT) for Prostate Cancer
Stereotactic Body Radiation Therapy (SBRT) for the Management of Carcinoma of the Prostate: Quality of Life Data After Primary Stereotactic Body Radiation Therapy for Localized Prostate Cancer
Source: ClinicalTrials.gov · Last updated 15 Sept 2025
Brief summary (registry, in English)
The purpose of this study is to learn the long term efficacy and side effects associated with utilizing Stereotactic Body Radiation Therapy (SBRT) radiation for prostate cancer utilizing the Elekta Versa or Agility System. SBRT uses advanced imaging techniques to deliver targeted radiation to a tumor. The Elekta Versa and Agility Systems are approved by the Food and Drug Association (FDA) for SBRT treatment of cancer. Traditional External beam radiation therapy (EBRT) for prostate carcinoma is typically done over the course of approximately 42-45 daily treatments SBRT is a way to condense this treatment into a course of 5 treatments, delivering more dose per day.
- Status (registry)
- Active, not recruiting
- Study type
- Interventional
- Enrollment
- 100 (estimated)
- First submitted
- 19 Mar 2019
- Start date
- 21 Oct 2016
- Primary completion date
- 31 Dec 2023
- Lead sponsor
- Hoag Memorial Hospital Presbyterian
- Diseases
- Prostate cancer
- NCT number
- NCT03889119
What you commit to
- Study type: Interventional
- Planned participants: 100
- From 21 Oct 2016 to the primary completion date, 31 Dec 2023
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previous radical surgery (prostatectomy), cryosurgery, or HIFU for prostate cancer
- Previous pelvic irradiation, prostate brachytherapy
- Previous or concurrent cytotoxic chemotherapy for prostate cancer
- There are no exclusions due to co-morbid disease or illnesses except for patients with severe inflammatory bowel disease
- No life expectancy restrictions will apply
- Performance Status will not be considered
Other
- Evidence of distant metastases
- Regional lymph node involvement
Who the study is looking for
- Histologically confirmed diagnosis of adenocarcinoma of the prostate History/physical examination with digital rectal examination of the prostate
- Histological evaluation of prostate biopsy with assignment of Gleason score to the biopsy material.
- Clinical stage T1-3 (AJCC 7th edition).
- Males age ≥ 18
- Patient must be able to provide study-specific informed consent prior to study entry.
- Willingness and ability to complete the Expanded Prostate Cancer Index Composite (EPIC) questionnaire
Age in the registry: 18 years to - · Sex: Male · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Hoag Memorial Hospital Presbyterian Coordinator of this site? Confirm its status | Irvine | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.